Drugs / ALF-5755
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01318525 | Oct 2010 → May 2012 | acute liver failure | Alfact Innovation | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALF-5755 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01318525 ↗ |
| Known as | Reg3α | “The human C-type lectin Reg3α, referred to as ALF-5755, improved survival in an animal model of acute liver failure” PMID 26983031 ↗ Mar 2016 |
| Modality | Protein / enzyme biologic | “The human C-type lectin Reg3α, referred to as ALF-5755” PMID 26983031 ↗ Mar 2016 |
| Route | Intravenous | “slow intravenous infusions over 10 minutes using automatic syringes” NCT01318525 ↗ |